PARP inhibitors – a cancer drug discovery story | Professor Ruth Plummer FMedSci

How does a new cancer drug go from laboratory discovery to hospital treatment? Professor Ruth Plummer FMedSci shares her story taking an ovarian cancer treatment from an academic drug discovery project to a treatment now licensed in the USA and Europe.

Professor Plummer is part of the team that discovered the ovarian cancer drug rucaparib (Rubraca®). Rucaparib inhibits the enzyme poly ADP ribose polymerase (PARP), and offers hope to the hundreds of women who are diagnosed each year with inoperable tumours.

Professor Plummer is Professor of Experimental Cancer Medicine at Newcastle University.

Follow her on Twitter http://twitter.com/plummer_ruth

Professor Plummer gave this presentation ‘Rucaparib – a story of academic cancer drug discovery and development’ as part of the Academy of Medical Sciences New Fellow’s Admissions Day 2018, held on 27 June. On this day, the Academy welcomed newly elected Fellows for their formal admission.

Read more about Professor Plummer’s work
https://www.ncl.ac.uk/nicr/staff/profile/ruthplummer.html#background

For more information about New Fellows Day 2018, visit
https://acmedsci.ac.uk/more/news/admissions-day-2018

Find the Academy of Medical Sciences online:
Website: http://acmedsci.ac.uk/
Twitter: http://twitter.com/AcMedSci
Facebook: http://www.facebook.com/acmedsci
Instagram: http://www.instagram.com/acmedsci/


Leave a Comment

We don't require your email address, or your name, for anyone to leave a comment. If you do add an email address, you may be notified if there are replies to your comment - we won't use it for any other purpose. Please make respectful comments, which add value, and avoid personal attacks on others. Links are not allowed in comments - 99% of spam comments, attempt to post links. Please describe where people may find additional information - for example "visit the UN website" or "search Google for..." rather than posting a link. Comments failing to adhere to these guidelines will not be published.